Core Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.36M Sell
1,132
-381
-25% -$389K 0.58% 47
2026
Q1
$1.39M Sell
1,513
-6
-0.4% -$6.08K 0.65% 42
2025
Q4
$1.63M Sell
1,519
-211
-12% -$202K 0.73% 39
2025
Q3
$1.32M Buy
1,730
+275
+19% +$205K 0.61% 46
2025
Q2
$1.13M Buy
1,455
+540
+59% +$420K 0.58% 48
2025
Q1
$756K Buy
915
+141
+18% +$117K 0.44% 56
2024
Q4
$598K Buy
774
+229
+42% +$190K 0.34% 64
2024
Q3
$483K Buy
545
+208
+62% +$187K 0.29% 77
2024
Q2
$305K Buy
337
+70
+26% +$56K 0.21% 101
2024
Q1
$208K Buy
+267
New +$190K 0.16% 131

Other funds holding LLY

Core Wealth Partners's LLY Position: Q2 2026 in Review

Core Wealth Partners reduced its Eli Lilly (LLY) stake by 25% in Q2 2026, selling an estimated $389K and leaving 1,132 shares worth $1.36M. The position accounts for 0.58% of the portfolio, ranked #47.

Core Wealth Partners first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.63M in Q4 2025. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Core Wealth Partners held 1,132 shares of Eli Lilly worth $1.36M as of Q2 2026.
  • Core Wealth Partners sold 381 Eli Lilly shares in Q2 2026, an estimated $389K.
  • Eli Lilly made up 0.58% of Core Wealth Partners's portfolio in Q2 2026, its #47 holding.
  • Core Wealth Partners first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • Core Wealth Partners's Eli Lilly position peaked at $1.63M in Q4 2025.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Core Wealth Partners's 13F filing for Q2 2026, filed 17 Jul 2026.